Neurocrine Biosciences (NASDAQ:NBIX) had its target price trimmed by Wedbush from $126.00 to $112.00 in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has an outperform rating on the stock.
A number of other analysts have also recently commented on NBIX. Mizuho boosted their price target on Neurocrine Biosciences from $117.00 to $119.00 and gave the stock a neutral rating in a research report on Friday, February 5th. Zacks Investment Research cut Neurocrine Biosciences from a buy rating to a hold rating in a research report on Thursday, April 15th. Raymond James initiated coverage on Neurocrine Biosciences in a research report on Monday, February 1st. They issued an outperform rating and a $163.00 price target on the stock. Canaccord Genuity reaffirmed a buy rating on shares of Neurocrine Biosciences in a research report on Thursday, January 21st. Finally, William Blair reaffirmed a buy rating on shares of Neurocrine Biosciences in a research report on Tuesday, January 26th. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $127.68.
NBIX stock opened at $96.16 on Monday. The business’s 50 day moving average price is $95.06 and its two-hundred day moving average price is $100.44. Neurocrine Biosciences has a fifty-two week low of $86.02 and a fifty-two week high of $136.26. The company has a market capitalization of $9.09 billion, a price-to-earnings ratio of 103.40 and a beta of 1.01.
In other news, Director Gary A. Lyons sold 1,600 shares of the company’s stock in a transaction on Monday, January 25th. The stock was sold at an average price of $120.03, for a total value of $192,048.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Malcolm Lloyd-Smith sold 1,700 shares of the company’s stock in a transaction on Wednesday, February 10th. The stock was sold at an average price of $119.96, for a total value of $203,932.00. Following the completion of the sale, the insider now owns 33,610 shares of the company’s stock, valued at $4,031,855.60. The disclosure for this sale can be found here. Insiders have sold a total of 23,426 shares of company stock worth $2,740,985 over the last three months. Insiders own 4.30% of the company’s stock.
Several large investors have recently bought and sold shares of the company. DSM Capital Partners LLC increased its stake in shares of Neurocrine Biosciences by 33.4% in the 4th quarter. DSM Capital Partners LLC now owns 1,116,380 shares of the company’s stock worth $107,006,000 after purchasing an additional 279,614 shares in the last quarter. Norges Bank purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $67,804,000. Brown Advisory Inc. increased its stake in Neurocrine Biosciences by 8.5% in the 4th quarter. Brown Advisory Inc. now owns 697,730 shares of the company’s stock worth $66,878,000 after buying an additional 54,588 shares in the last quarter. Eaton Vance Management increased its stake in Neurocrine Biosciences by 310.8% in the 4th quarter. Eaton Vance Management now owns 528,489 shares of the company’s stock worth $50,656,000 after buying an additional 399,834 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Neurocrine Biosciences by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,521 shares of the company’s stock worth $45,483,000 after buying an additional 3,989 shares in the last quarter. Hedge funds and other institutional investors own 95.25% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc, a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids.
Read More: What is the Coverage Ratio?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.